Regenerative medicine legislation in Japan for fast provision of cell therapy products.
A new legal framework consisting of three laws for cell-based and tissue-based therapies went into effect in November 2014 in Japan. Among the provisions of the laws, the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) allows conditional and time-limited approval for regenerative medical products based on the ensured safety and estimated efficacy in small-scale clinical trials. The new legislation is expected to accelerate safe and fast provision of the innovative products to patients with intractable diseases.
Unit of Regenerative Medicine, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation, Chuo-ku, Kobe, Japan.
Y
Y
Fujita
Unit of Regenerative Medicine, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation, Chuo-ku, Kobe, Japan.|Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Chuo-ku, Kobe, Japan.
A
A
Kawamoto
D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D007564:Japan; D044968:Regenerative Medicine / Q000331:legislation & jurisprudence*; D013997:Time Factors